Chinese biotech firm CStone Pharmaceuticals' (HKEX: 2616) is mulling over a potential sale of the business, according to sources cited by Bloomberg.
CStone is exploring strategic options for the future of the enterprise and has drafted in investment bank Goldman Sachs to sound out interest from prospective buyers, the report states.
Bloomberg does not name the sources due to their preference to remain anonymous, but they believe that acquiring CStone could be of interest to other Chinese or global pharma companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze